{"id":"W4415940075","doi":"10.1016/j.annonc.2025.08.971","title":"548P Phase I/Ib trial of inavolisib (INAVO) + pertuzumab (P) + trastuzumab (H) for PIK3CA-mutated (mut), HER2-positive advanced breast cancer (HER2+ aBC)","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Pertuzumab; Trastuzumab; Palbociclib; Fulvestrant; Chemotherapy; Cohort; Breast cancer; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000370288,0.0004464775,0.001755765,0.000402166,0.0001194015,0.00000792345,0.0003172001,0.0003686661,0.0002412125],"category_scores_gemma":[0.0002717825,0.0004118949,0.0004664631,0.00066024,0.0006322585,0.0002326152,0.00008318984,0.0003530473,0.000003446246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005085304,"about_ca_system_score_gemma":0.001877164,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005000571,"about_ca_topic_score_gemma":0.0001560314,"domain_scores_codex":[0.9969702,0.0001857732,0.00113345,0.0006539897,0.0003416054,0.0007149266],"domain_scores_gemma":[0.9963877,0.0006647699,0.0007335742,0.0005373313,0.00148236,0.0001942165],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3149732,0.005267613,0.0001059841,0.0004596912,0.00122414,0.0000541302,0.001344082,0.0001567511,0.0227432,0.0009799962,0.001906768,0.6507845],"study_design_scores_gemma":[0.6013374,0.06394982,0.005891231,0.002375709,0.001488137,0.0004113735,0.003171988,0.0007841747,0.1730513,0.004720155,0.1417248,0.001093953],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9555779,0.003689385,0.003628737,0.02510911,0.001410448,0.004316468,0.001764538,0.0001308166,0.004372672],"genre_scores_gemma":[0.9927827,0.0009302416,0.001789281,0.002113806,0.0003737584,0.0007449671,0.0001469196,0.00007288426,0.001045449],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6496905,"threshold_uncertainty_score":0.9998333,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0452135782774123,"score_gpt":0.4467083163830423,"score_spread":0.40149473810563,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}